Congress Program

* Subject to Change

Thursday, 13 December




Welcome and Opening of the Congress
Nir Peled, 
Israel | Chairman

Keynote Lecture: Recent Updates in the Algorithm of NSCLC

Overview of the updates in NSCLC therapy over the last 2 years
Silvia Novello, University of Turin, Italy


Session 1
Screening for Lung Cancer – If, How and When?
Chair: Robert Pirker, Austria


Are we Facing a Revolution in Screening for Lung Cancer in Europe Now?   

Current Consensus and the NELSON Recent Summary + Impact on Europe
Robert Pirker, Medical University of Vienna, Austria


Is There a Recommended Methodology in Screening Programs?

Mainly 2D vs. 3D technology of CT & measurement, time gaps between rounds of screening
Matthijs Oudkerk, University of Groningen, The Netherlands


Biomarkers to Serve Decisions in Screening Program

Review of biomarkers pre or post PSN finding
Mattia Boeri, Fondazione IRCCS Istituto Nazionale Tumori, Italy

SBRT for Early Disease
SBRT - overview, success, advantage & limitations
Aaron Allen, Davidoff Center, Israel


Coffee Break, Networking and Poster Viewing


Session 2
Controversies in Pathology - Tissue Exhaustion, NGS and Liquid Alternative
Chair: Phillipe Taniere, UK


Challenges in the Pathology Lab

Advise tissue management and the required histology report
Phillipe Taniere, University Hospitals Birmingham NHS Foundation Trust, UK


Molecular Profiling in Lung Cancer - Upfront or Reflex Multiplex Approach?

Score of technologies considerations
Patrick Pauwels, University Hospital Antwerp, Belgium


Liquid Biopsy - on Top or Replace the Pathology Lab?

Review of available methods, time to test (upfront/on progression) advantages
Christian Rolfo, University of Maryland School of Medicine, USA



Bio-Informatics - Outsource or in-house Analysis?

Tools for bio-informatics and data management, pro-cons for outsource or in-house
Laila C. Roisman, Soroka Medical Center, Israel


Annotating the NGS Report - Who's responsibility?
Present examples of NGS reports and tips for annotation. Who's responsible - the pathologist or the oncologist?
Miguel Ángel Molina, Pangaea Oncology, Spain


Lunch Break, Networking and Poster Viewing


Session 3
Debates in Thoracic Intervention
Chair: Milton Saute, Israel


Mini-Procedural Approaches in Thoracic Surgery

Review of procedures including LN sampling data
Pierluigi Novellis, Humanitas Research Hospital, Italy


Stage IA (T1aN0M0) Lobectomy vs. Segmentectomy
Pro-cons each approach
Pierluigi Novellis
, Humanitas Research Hospital, Italy


Do we still Perform Pneumonectomy?

Review of indication, mortality, risks and outcome
Milton Saute, Rabin Medical Center - Campus Beilinson, Israel


Coffee Break, Networking and Poster Viewing


Session 4
Debates in Stage III Disease
Chair: Nir Peled, Israel


Dosing for Chemo-RT and the "no fly zone"
Review of the dose for Chemo-RT and discuss centralize SBRT as an option
Raphael Pfeffer, Assuta Medical Center, Israel


Consolidation Therapy Post Chemo-RT. A New Era?
Review of adjuvant therapies particularly for IO (Durvalumab)
Nir PeledSoroka Medical Center, Israel


End of Day One

Friday, 14 December




Session 5
Controversies in Advanced NSCLC
Chair: Anne-Marie C. Dingemans, Netherlands


EGFR Therapy: How should we Start?
Discuss recent data of Osimertinib and its role in 1st or 2nd line + resistant pathways
Pascale Tomasini, Hospital Nord, France


ALK Disease: Best First or Later and Do we Care about Variants?
Discuss recent data and sequence of therapy pro-cons with/out brain mets
Petros Christopoulos, University of Heidelberg, Germany

Is there a limit to focal treatment? Strategy for treatment of brain metastases in NSCLC
Review of the literature and technologies to allow avoidance from WBRT
Deborah BlumenthalTel Aviv Sourasky Medical Center, Israel

What is Oligo Metastatic Disease in Lung Cancer?
Anne-Marie C. Dingemans, Maastricht University Medical Center, Netherlands


Coffee Break, Networking and Poster Viewing


Session 6
Debates in Immunotherapy
Chair: Wilfried Eberhardt, Germany


Recent Updates in Immunotherapy in Lung Cancer (NSCLC & SCLC)
Review of the last two years update in IO (NSCLC and SCLC)
Nir PeledSoroka Medical Center, Israel


PDL1>50% - Should we go Single or Combo?
Discuss clinical considerations for protocol selection among TMB, tumor burden, disease dissemination etc
Nir Peled, Soroka Medical Center, Israel


What are the Best Biomarkers for IO in Lung Cancer?
Review updates and score predictive biomarkers for IO including PDL1, PDL2, TMB, KRAS, STK11 and others
Miguel Ángel Molina, Pangaea Oncology, Spain


Re-Challenge of IO upon Toxicity or Progression. When, Why and Why not?
Discuss the considerations and the evidence for renewing IO therapy after toxicity or after remission and progression
Wilfried Eberhardt, University of Duisburg-Essen, Germany

Disease Progression on IO. What are the Options?
Mechanism and clinical scenarios for disease progression under IO. Should we stop IO or rather add chemo or other maneuvers to control the disease
Rudolf M. HuberUniversity of Munich, Germany


Lunch Break, Networking and Poster Viewing


Session 7
Debates in Small Cell Lung Cancer
Chair: Paul Van Houtte, Belgium


Treatment Algorithm in SCLC
Review the recent updates in the therapy for SCLC, including IO, RovaT and others
Wilfried EberhardtUniversity of Duisburg-Essen, Germany


PCI or MRI Monitoring in Limited SCLC
Challenge the PCI recommendation in SCLC
Paul Van Houtte,
Institute Jules Bordet, Belgium


Coffee Break, Networking and Poster Viewing


Session 8
Oral Presentations of Selected Abstracts
Chair: Nir Peled, Israel

Inter-Tumor Heterogeneity of PD-L1 Expression in Non-Small Cell Lung Cancer
Yuichi Saito, Sho Horiuchi, Hiroaki Morooka, Takayuki Ibi, Nobumasa Takahashi, Tomohiko Ikeya, Eishin Hoshi, Yoshihiko Shimizu, 
Saitama Cardiovascular and Respiratory Center, Japan

Circulating Tumor DNA Signature to Predict Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Roxana Grinberg, Laila Roisman, Smadar Geva, Martina Lefterova, Katie Quinn, Lior Soussan Gutman, Addie Dvir, Roi Yair, Tal Twito, Richard Lanman,
Nir Peled, Soroka University Medical Center, Israel


Congress Closing